The Jett Foundation Fighting Duchenne Muscular Dystrophy

Jett Foundation Requests Marathon Convene a Meeting of Stakeholders to Discuss Re-evaluation of Deflazacort Pricing

February 17, 2017

In response to the pause in commercialization of EMFLAZA™ (deflazacort) announced by Marathon Pharmaceuticals earlier this week, Jett Foundation, in collaboration with Parent Project Muscular Dystrophy (PPMD), requests that Marathon convene a meeting of stakeholders including Duchenne advocacy groups, clinicians, health insurance plans, and pharmacy benefit managers, to seek evidence-based input and re-evaluate their pricing model.  

Jett Foundation looks forward to Marathon’s response to this request, and plans to keep the patient community informed of our communications. 

Show Buttons
Hide Buttons